NGM NGM Biopharmaceuticals Inc

NGM Biopharmaceuticals (NGM - Research Report) received a Hold rating and price target from Piper Sandler analyst Swapnil Malekar today. The company's shares closed today at $3.41.Malekar covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Mirati Therapeutics, and NGM Biopharmaceuticals. According to TipRanks, Malekar has an average return of -13.1% and a 20.00% success rate on recommended stocks. In addition to Piper Sandler, NGM Biopharmaceuticals also received a Hold from Jefferies's Dennis Ding in a report issued today. However, on October 7, B.Riley Financial maintained a Buy rating on NGM Biopharmaceuticals (NASDAQ: NGM).See today’s best-performing stocks on TipRanks >>The company has a one-year high of $21.
https://www.tipranks.com/news/blurbs/ngm-biopharmaceuticals-ngm-was-downgraded-to-a-hold-rating-at-piper-sandler?utm_source=advfn.com&utm_medium=referral